Rosiglitazone sensitizes MDA-MB-231 breast cancer cells to anti-tumour effects of tumour necrosis factor-alpha, CH11 and CYC202. (Q40105347)
Jump to navigation
Jump to search
scientific article
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Rosiglitazone sensitizes MDA-MB-231 breast cancer cells to anti-tumour effects of tumour necrosis factor-alpha, CH11 and CYC202. |
scientific article |
Statements
1 reference
Rosiglitazone sensitizes MDA-MB-231 breast cancer cells to anti-tumour effects of tumour necrosis factor-alpha, CH11 and CYC202. (English)
1 reference
Manali Mody
1 reference
Nachiket Dharker
1 reference
Mark Bloomston
1 reference
Pei-Shan Wang
1 reference
Theodore S Glickman
1 reference
Timothy McCaffrey
1 reference
Zhaoqing Yang
1 reference
Anne Pumfery
1 reference
Daniel Lee
1 reference
Matthew D Ringel
1 reference
Joseph J Pinzone
1 reference
1 June 2007
1 reference
1 reference
Identifiers
1 reference